Substrate-induced changes in the density of peptide transporter PEPT1 expressed in Xenopus oocytes.
The adaptation of the capacity of the intestinal peptide transporter PEPT1 to varying substrate concentrations may be important with respect to its role in providing bulk quantities of amino acids for growth, development, and other nutritional needs. In the present study, we describe a novel phenomenon of the regulation of PEPT1 in the Xenopus oocyte system. Using electrophysiological and immunofluorescence methods, we demonstrate that a prolonged substrate exposure of rabbit PEPT1 (rPEPT1) caused a retrieval of transporters from the membrane. Capacitance as a measure of membrane surface area was increased in parallel with the increase in rPEPT1-mediated transport currents with a slope of approximately 5% of basal surface per 100 nA. Exposure of oocytes to the model peptide Gly-l-Gln for 2 h resulted in a decrease in maximal transport currents with no change of membrane capacitance. However, exposure to substrate for 5 h decreased transport currents but also, in parallel, surface area by endocytotic removal of transporter proteins from the surface. The reduction of the surface expression of rPEPT1 was confirmed by presteady-state current measurements and immunofluorescent labeling of rPEPT1. A similar simultaneous decrease of current and surface area was also observed when endocytosis was stimulated by the activation of PKC. Cytochalasin D inhibited all changes evoked by either dipeptide or PKC stimulation, whereas the PKC-selective inhibitor bisindolylmaleimide only affected PKC-stimulated endocytotic processes but not substrate-dependent retrieval of rPEPT1. Coexpression experiments with human Na(+)-glucose transporter 1 (hSGLT1) revealed that substrate exposure selectively affected PEPT1 but not the activity of hSGLT1.
Mertl
Manuela
M
Molecular Nutrition Unit, Am Forum 5, Freising 85350, Germany.
Daniel
Hannelore
H
Kottra
Gabor
G
D000818:Animals; D002462:Cell Membrane / Q000378:metabolism*; D015638:Cytochalasin D / Q000494:pharmacology; D004151:Dipeptides / Q000378:metabolism; D015536:Down-Regulation; D025802:Electric Capacitance; D004705:Endocytosis / Q000187:drug effects; D004789:Enzyme Activation; D020536:Enzyme Activators / Q000494:pharmacology; D018014:Gene Transfer Techniques; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007700:Kinetics; D008301:Maleimides / Q000494:pharmacology; D008564:Membrane Potentials; D018613:Microscopy, Confocal; D009865:Oocytes / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D018408:Patch-Clamp Techniques; D000074011:Peptide Transporter 1; D015240:Phorbol 12,13-Dibutyrate / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D021381:Protein Transport; D011817:Rabbits; D051269:Sodium-Glucose Transporter 1 / Q000378:metabolism; D027981:Symporters / Q000235:genetics / Q000378:metabolism*; D014982:Xenopus laevis / Q000378:metabolism*
D004151:Dipeptides; D020536:Enzyme Activators; D007211:Indoles; D008301:Maleimides; D000074011:Peptide Transporter 1; D047428:Protein Kinase Inhibitors; C495674:SLC5A1 protein, human; D051269:Sodium-Glucose Transporter 1; D027981:Symporters; C039788:glycylglutamine; D015638:Cytochalasin D; D015240:Phorbol 12,13-Dibutyrate; D011493:Protein Kinase C; C088060:bisindolylmaleimide